252 related articles for article (PubMed ID: 34230160)
1. Salvage Radiation Treatment for Primary Refractory Diffuse Large B-cell Lymphoma After Chimeric Antigen Receptor (CAR) T-cell Therapy: A Case Report.
Wang K; Prabhu AV; Sasapu A; Lewis GD
Anticancer Res; 2021 Jul; 41(7):3635-3638. PubMed ID: 34230160
[TBL] [Abstract][Full Text] [Related]
2. Radiation Priming Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma With High Tumor Burden.
Qu C; Ping N; Kang L; Liu H; Qin S; Wu Q; Chen X; Zhou M; Xia F; Ye A; Kong D; Li C; Yu L; Wu D; Jin Z
J Immunother; 2020 Jan; 43(1):32-37. PubMed ID: 31219975
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis.
Kim J; Cho J; Yoon SE; Kim WS; Kim SJ
Cancer Res Treat; 2023 Jul; 55(3):1031-1047. PubMed ID: 36915243
[TBL] [Abstract][Full Text] [Related]
4. Assessing the role of radiotherapy in patients with refractory or relapsed high-grade B-cell lymphomas treated with CAR T-cell therapy.
Ababneh HS; Abramson JS; Johnson PC; Patel CG
Radiother Oncol; 2022 Oct; 175():65-72. PubMed ID: 35952976
[TBL] [Abstract][Full Text] [Related]
5. Case Report: Subtotal Lymphoid and Total Marrow Irradiation as Bridge Therapy to CD19-Directed CAR T Cells in a Chemorefractory DLBCL With Leukemic Involvement.
Saldi S; Perriello VM; Falini L; Ruggeri L; Fulcheri C; Ciardelli S; Innocente A; Ballanti S; Baffa N; Flenghi L; Pierini A; Aristei C; Falini B
Front Immunol; 2022; 13():934700. PubMed ID: 35911683
[TBL] [Abstract][Full Text] [Related]
6. Bridging Radiation Rapidly and Effectively Cytoreduces High-Risk Relapsed/Refractory Aggressive B Cell Lymphomas Prior to Chimeric Antigen Receptor T Cell Therapy.
Hubbeling H; Silverman EA; Michaud L; Tomas AA; Shouval R; Flynn J; Devlin S; Wijetunga NA; Tringale KR; Batlevi C; Dahi P; Giralt S; Lin R; Park J; Scordo M; Sauter C; Shah G; Hajj C; Salles G; Schoder H; Palomba ML; Perales MA; Yahalom J; Imber BS
Transplant Cell Ther; 2023 Apr; 29(4):259.e1-259.e10. PubMed ID: 36587744
[TBL] [Abstract][Full Text] [Related]
7. Radiation therapy prior to CAR T-cell therapy in lymphoma: impact on patient outcomes.
Figura NB; Sim AJ; Jain MD; Chavez JC; Robinson TJ
Expert Rev Hematol; 2022 Dec; 15(12):1023-1030. PubMed ID: 36369950
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of salvage chemotherapy regimens and chimeric antigen T-cell receptor therapies in relapsed and refractory diffuse large B cell lymphoma: a network meta-analysis of clinical trials.
Gong IY; Aminilari M; Landego I; Hueniken K; Zhou Q; Kuruvilla J; Hodgson DC
Leuk Lymphoma; 2023 Oct; 64(10):1643-1654. PubMed ID: 37548344
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of chimeric antigen receptor T cell therapy in relapsed/refractory diffuse large B-cell lymphoma with different HBV status: a retrospective study from a single center.
Kong D; Ping N; Gao X; Zou R; Wang P; Wu D; Jin Z; Qu C
Front Immunol; 2023; 14():1200748. PubMed ID: 37292195
[TBL] [Abstract][Full Text] [Related]
10. Salvage radiotherapy for primary refractory and relapsed diffuse large B-Cell lymphoma.
Brooks ED; Fang P; Pinnix CC
Br J Radiol; 2021 Nov; 94(1127):20210360. PubMed ID: 34378402
[TBL] [Abstract][Full Text] [Related]
11. Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group.
Ng AK; Yahalom J; Goda JS; Constine LS; Pinnix CC; Kelsey CR; Hoppe B; Oguchi M; Suh CO; Wirth A; Qi S; Davies A; Moskowitz CH; Laskar S; Li Y; Mauch PM; Specht L; Illidge T
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):652-669. PubMed ID: 29413279
[TBL] [Abstract][Full Text] [Related]
12. Potential synergy between radiotherapy and CAR T-cells - a multicentric analysis of the role of radiotherapy in the combination of CAR T cell therapy.
Fan J; Adams A; Sieg N; Heger JM; Gödel P; Kutsch N; Kaul D; Teichert M; von Tresckow B; Bücklein V; Goesmann G; Li M; Struve N; Trommer M; Linde P; Rosenbrock J; Celik E; Penack O; Stuschke M; Subklewe M; Belka C; von Bergwelt-Baildon M; Borchmann P; Marnitz S; Baues C
Radiother Oncol; 2023 Jun; 183():109580. PubMed ID: 36842663
[TBL] [Abstract][Full Text] [Related]
13. ASTCT Committee on Practice Guidelines Survey on Evaluation & Management of Diffuse Large B-cell Lymphoma after Failure of Chimeric Antigen Receptor T Cell Therapy (CAR-T) Therapy.
Ahmed N; Kumar A; Kharfan-Dabaja MA; DeFilipp Z; Herrera A; Hashmi S; Dholaria B; Perales MA; Carpenter PA; Hamadani M
Transplant Cell Ther; 2022 Sep; 28(9):523-529. PubMed ID: 35671986
[TBL] [Abstract][Full Text] [Related]
14. Health Care Resource Utilization and Total Costs of Care Among Patients with Diffuse Large B Cell Lymphoma Treated with Chimeric Antigen Receptor T Cell Therapy in the United States.
Keating SJ; Gu T; Jun MP; McBride A
Transplant Cell Ther; 2022 Jul; 28(7):404.e1-404.e6. PubMed ID: 35354101
[TBL] [Abstract][Full Text] [Related]
15. Novel Immune-Based treatments for Diffuse Large B-Cell Lymphoma: The Post-CAR T Cell Era.
Atallah-Yunes SA; Robertson MJ; Davé UP; Ghione P; Perna F
Front Immunol; 2022; 13():901365. PubMed ID: 35720352
[TBL] [Abstract][Full Text] [Related]
16. Relapsed or Refractory Diffuse Large B-Cell Lymphoma: "Dazed and Confused".
Kesireddy M; Lunning M
Oncology (Williston Park); 2022 Jun; 36(6):366-375. PubMed ID: 35723942
[TBL] [Abstract][Full Text] [Related]
17. Integrating CAR-T cell therapy into the management of DLBCL: what we are learning.
Martino M; Canale FA; Porto G; Verduci C; Utano G; Policastro G; Germanò J; Alati C; Santoro L; Imbalzano L; Pitea M
Expert Opin Biol Ther; 2023; 23(12):1277-1285. PubMed ID: 38078446
[TBL] [Abstract][Full Text] [Related]
18. Characteristics and treatment patterns of relapsed/refractory diffuse large B-cell lymphoma in patients receiving ≥3 therapy lines in post-CAR-T era.
Xie J; Wu A; Liao L; Nastoupil LJ; Du EX; Noman A; Chen L
Curr Med Res Opin; 2021 Oct; 37(10):1789-1798. PubMed ID: 34344238
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma after second-line salvage chemotherapy: A retrospective study.
Yagi Y; Kanemasa Y; Sasaki Y; Sei M; Matsuo T; Ishimine K; Hayashi Y; Mino M; Ohigashi A; Morita Y; Tamura T; Nakamura S; Okuya T; Shimizuguchi T; Shingai N; Toya T; Shimizu H; Najima Y; Kobayashi T; Haraguchi K; Doki N; Okuyama Y; Shimoyama T
Cancer Med; 2023 Sep; 12(17):17808-17821. PubMed ID: 37635630
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic effects of chimeric antigen receptor T cells (CAR-T) on relapse/refractory diffuse large B-cell lymphoma (R/R DLBCL): a meta-analysis.
Cao HH; Wang LL; Geng CK; Mao WW; Yang LL; Ma Y; He M; Zhang R; Zhou YY; Liu LQ; Hu XJ; Yu JX; Yang L; Shen XF; Yin LF; Gu XZ; Shen ZL
Eur Rev Med Pharmacol Sci; 2020 May; 24(9):4921-4930. PubMed ID: 32432755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]